20,000 Shares in Revolution Medicines, Inc. $RVMD Purchased by Raiffeisen Bank International AG

Raiffeisen Bank International AG acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $921,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in shares of Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the last quarter. California State Teachers Retirement System grew its holdings in Revolution Medicines by 0.3% during the second quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock valued at $5,153,000 after purchasing an additional 437 shares during the period. CWM LLC increased its position in Revolution Medicines by 171.3% in the second quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after buying an additional 579 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Revolution Medicines by 1.6% in the third quarter. Arizona State Retirement System now owns 41,299 shares of the company’s stock valued at $1,929,000 after buying an additional 646 shares during the period. Finally, Avanza Fonder AB raised its stake in shares of Revolution Medicines by 17.5% in the third quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock valued at $202,000 after buying an additional 647 shares during the period. 94.34% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Mark A. Goldsmith sold 15,394 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $1,182,567.08. Following the transaction, the insider owned 232,469 shares of the company’s stock, valued at approximately $17,858,268.58. This represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Jack Anders sold 10,000 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the completion of the sale, the chief financial officer owned 108,065 shares in the company, valued at $10,590,370. This trade represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 173,792 shares of company stock valued at $15,239,440. 8.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on RVMD shares. JPMorgan Chase & Co. increased their price target on Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. Wolfe Research started coverage on shares of Revolution Medicines in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 target price for the company. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines has an average rating of “Buy” and an average price target of $78.94.

Revolution Medicines Trading Down 0.9%

Shares of Revolution Medicines stock opened at $101.83 on Monday. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $124.49. The company has a market cap of $19.69 billion, a price-to-earnings ratio of -19.70 and a beta of 1.00. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16. The company’s 50-day moving average price is $96.62 and its 200-day moving average price is $68.45.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.